Ten recommendations to unlock the potential of big data for public health in the EU

On 20 January 2020 the joint Big Data Task Force of EMA and the Heads of Medicines Agencies (HMA) proposed ten priority actions for the European medicines regulatory network.

In January 2020, the HMA/EMA Task Force on Big Data published its final report (phase two) containing practical recommendations on how the European medicines regulatory network could make best use of big data by evolving its approach to data use and evidence generation in support of innovation and public health.

The report aims to inform strategic decision-making and planning by the HMA and EMA and to input to the EU Network Strategy to 2025. The report will support regulators and stakeholders seizing the opportunity for data- driven, evidence-based, robust decision-making that will underpin the development, authorisation and on-market safety and effectiveness monitoring of medicines in a rapidly evolving data and analytics landscape.

Read more online
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /